Trevena Inc - Asset Resilience Ratio
Trevena Inc (TRVN) has an Asset Resilience Ratio of 35.20% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Trevena Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2019)
This chart shows how Trevena Inc's Asset Resilience Ratio has changed over time. See Trevena Inc (TRVN) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Trevena Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Trevena Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $17.96 Million | 35.2% |
| Total Liquid Assets | $17.96 Million | 35.20% |
Asset Resilience Insights
- Very High Liquidity: Trevena Inc maintains exceptional liquid asset reserves at 35.20% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Trevena Inc Industry Peers by Asset Resilience Ratio
Compare Trevena Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Trevena Inc (2011–2019)
The table below shows the annual Asset Resilience Ratio data for Trevena Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 7.45% | $3.50 Million | $46.99 Million | -35.37pp |
| 2018-12-31 | 42.81% | $28.59 Million | $66.78 Million | -25.31pp |
| 2017-12-31 | 68.13% | $49.54 Million | $72.72 Million | -7.17pp |
| 2016-12-31 | 75.30% | $86.33 Million | $114.65 Million | +3.52pp |
| 2015-12-31 | 71.78% | $125.86 Million | $175.35 Million | +6.52pp |
| 2014-12-31 | 65.26% | $70.70 Million | $108.34 Million | +64.00pp |
| 2012-12-31 | 1.26% | $102.00K | $8.09 Million | +0.79pp |
| 2011-12-31 | 0.47% | $92.00K | $19.41 Million | -- |
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the… Read more